Gene therapy for rare retinal disorder to cost $425,000 per eye

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited ...

Posted: Jan 4, 2018 9:16 AM
Updated: Jan 4, 2018 9:16 AM

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.

Spark Therapeutics Inc., the Philadelphia-based maker of voretigene neparvovec, announced Wednesday in a statement that it reached an agreement in principle with Harvard Pilgrim and affiliates of-Express Scripts to make the one-time treatment available to patients with a rare genetic defect that often leads to blindness.

Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness

Spark Therapeutics set the price for the gene therapy at $425,000 per eye

The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.

In some cases, the gene therapy will be available under an "outcomes-based rebate arrangement." The company also stated that its proposal to the Centers for Medicare and Medicaid Services, the government program that covers about 100 million Americans, would allow installment payments for the drug.

"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed," said Jennifer Luddy, a spokeswoman for Express Scripts.

At least one patient advocate disagrees.

"The new payment models announced today are merely a way to disguise a price that is simply too high," David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement. "Spark Therapeutics is charging as much for Luxturna as they think they can get away with."

Spark Therapeutics CEO Jeff Marrazzo co-authored a recent blog post in the journal Health Affairs that said "the current payment system -- accustomed to ongoing treatment of chronic diseases -- creates significant challenges" for gene therapies and other treatments.

One-time-only treatments for rare genetic disorders are still unique, he noted.

The drug is intended for patients with retinal dystrophy due to a mutation of the RPE65 gene. This rare genetic defect causes severe visual impairment beginning in infancy and can eventually lead to blindness. The company believes the total "population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.

The drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.

Luxturna is only the third gene therapy approved for use in the United States; two others were also approved in 2017. This is the first to correct an inherited genetic mutation.

Luxturna-is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure. The drug supplies a third gene -- a normal RPE65 gene -- to cells in the retina, a layer of tissue lining the back of the eye.-This third version of the gene does not remove or replace the two mutated genes causing the disease, which remain inside the cells. However, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.

In the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company. Risks of the treatment include cataracts, elevated eye pressure, retinal tears and holes and inflammation.

The company's offer of unusual payer models, including rebates and installment payments, will "help ensure patients' individual financial situation does not hinder access to treatment," da Silva said.

"New technologies such as gene and cell therapies hold out the potential to transform medicine," FDA Commissioner Dr. Scott Gottlieb-said in a statement announcing the August approval of Kymriah, considered to be the first gene therapy to be approved for the US market.

Kymriah is a leukemia treatment made by pharmaceutical giant Novartis. Similar to Luxturna, Kymriah is a one-time treatment, and its price tag is $475,000. However, Novartis said this price will not be charged to patients who do not respond within a month of treatment.

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 710607

Reported Deaths: 13248
CountyCasesDeaths
Marion968581722
Lake51908949
Allen39337672
Hamilton34643406
St. Joseph34306543
Elkhart27477432
Vanderburgh22099394
Tippecanoe21927213
Porter17987301
Johnson17571374
Hendricks16854310
Clark12715190
Madison12367337
Vigo12240244
Monroe11510166
LaPorte11204204
Delaware10382184
Howard9698211
Kosciusko9165114
Hancock8014139
Bartholomew7913155
Warrick7702155
Floyd7568176
Wayne6917198
Grant6855171
Boone6568100
Morgan6414138
Dubois6091117
Marshall5801109
Dearborn571276
Cass5698104
Henry5588101
Noble543683
Jackson494172
Shelby481395
Lawrence4349118
Gibson429589
Harrison429171
Clinton420953
Montgomery418986
DeKalb413284
Whitley382239
Huntington379780
Miami373365
Knox367189
Steuben367157
Putnam353460
Jasper352546
Wabash348178
Adams338253
Ripley335469
Jefferson318080
White308854
Daviess289999
Wells286881
Decatur279592
Fayette277362
Greene271085
Posey269533
Scott261553
Clay255445
LaGrange255470
Randolph236080
Washington231631
Spencer228131
Jennings225448
Fountain209345
Sullivan208042
Starke206252
Owen192756
Fulton192140
Jay186429
Carroll186120
Perry181436
Orange178353
Rush170824
Vermillion166343
Franklin166035
Tipton161543
Parke144616
Blackford133931
Pike130734
Pulaski114345
Newton104234
Brown100740
Crawford97914
Benton97413
Martin83115
Warren80215
Switzerland7698
Union70110
Ohio56011
Unassigned0408

Ohio Coronavirus Cases

Data is updated nightly.

Cases: 1058395

Reported Deaths: 19033
CountyCasesDeaths
Franklin1229981360
Cuyahoga1080042072
Hamilton785031170
Montgomery50326998
Summit45710915
Lucas40568768
Butler37858572
Stark31586896
Lorain24333473
Warren23964293
Mahoning21029584
Lake20143365
Clermont19480229
Delaware18162130
Licking16185207
Fairfield15796197
Trumbull15666461
Medina14961259
Greene14765236
Clark13697293
Wood12828185
Portage12481196
Allen11374229
Richland11102198
Miami10568214
Muskingum8729127
Wayne8619209
Columbiana8589226
Pickaway8454121
Marion8409135
Tuscarawas8393240
Erie7644154
Hancock6746124
Ross6727146
Ashtabula6563166
Geauga6563146
Scioto6314101
Belmont5657159
Union560247
Lawrence5483102
Jefferson5372149
Huron5333114
Darke5285121
Sandusky5208120
Seneca5163120
Washington5095108
Athens509256
Auglaize477683
Mercer473785
Shelby458092
Knox4418108
Madison426559
Putnam423199
Ashland414488
Fulton411667
Defiance405596
Crawford3894102
Brown387755
Logan375176
Preble372498
Clinton364060
Ottawa359578
Highland348460
Williams330074
Champaign322357
Jackson309351
Guernsey308749
Perry290949
Fayette278448
Morrow277239
Hardin265964
Henry265066
Coshocton261058
Holmes255199
Van Wert239863
Pike234231
Gallia233346
Adams230252
Wyandot228354
Hocking210759
Carroll189747
Paulding169239
Meigs141738
Noble133037
Monroe129041
Morgan107723
Harrison105936
Vinton81614
Unassigned02
Fort Wayne
Partly Cloudy
47° wxIcon
Hi: 48° Lo: 29°
Feels Like: 39°
Angola
Clear
46° wxIcon
Hi: 48° Lo: 26°
Feels Like: 40°
Huntington
Cloudy
48° wxIcon
Hi: 49° Lo: 27°
Feels Like: 44°
Fort Wayne
Partly Cloudy
47° wxIcon
Hi: 47° Lo: 28°
Feels Like: 39°
Lima
Cloudy
45° wxIcon
Hi: 48° Lo: 29°
Feels Like: 37°
Patchy frost is expected Thursday night and near seasonable highs are on the way for Friday afternoon.
WFFT Radar
WFFT Temperatures
WFFT National

Community Events